4-fluoro-N-[4-(thiazol-2-yl)benzyl]benzenesulfonamide → N-[4-(thiazol-2-yl)benzyl]pyridin-3-ylsulfonamide
Reaktionsgleichung
C(OC(N(CC([O-])=O)[C:9]1[CH:14]=[CH:13][CH:12]=[C:11](CO)[N:10]=1)=O)(C)(C)C.FC1C=CC([S:28]([NH:31][CH2:32][C:33]2[CH:38]=[CH:37][C:36]([C:39]3[S:40][CH:41]=[CH:42][N:43]=3)=[CH:35][CH:34]=2)(=[O:30])=[O:29])=CC=1>>[S:40]1[CH:41]=[CH:42][N:43]=[C:39]1[C:36]1[CH:35]=[CH:34][C:33]([CH2:32][NH:31][S:28]([C:12]2[CH:11]=[N:10][CH:9]=[CH:14][CH:13]=2)(=[O:30])=[O:29])=[CH:38][CH:37]=1Komponenten
3
Versuchsvorschrift
Reaction and post-treatment were carried out in the same manner as in Example 2-(a) except for using tert-butyl([tert-butoxycarbonyl(6-hydroxymethylpyridin-2-yl)amino]acetate (101 mg, 0.298 mmol) obtained in Reference Example 3-(b), and using 4-fluoro-N-[4-(thiazol-2-yl)benzyl]benzenesulfonamide (105 mg, 0.301 mmol) obtained in Reference Example 6 in place of N-[4-(thiazol-2-yl)benzyl]pyridin-3-ylsulfonamide to afford the title compound (181 mg) as a white foam. (Yield: 91%)
Aufarbeitung
- custom